Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lois Shepherd

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Blood|May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011John C Byrd, Kanti Rai, Bercedis L Peterson, et al.
Oncotarget|April 9, 2016
A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trialMelanie Spears, Nicola Lyttle, Alister D'Costa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011Vicki A Morrison, Kanti R Rai, Bercedis L Peterson, et al.
Cancer|September 24, 2004
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)Michael Crump, Tara Baetz, Stephen Couban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16Michael Crump, Stefan Gluck, Dongsheng Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplantA Keith Stewart, Christine I Chen, Kang Howson-Jan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter studyFabio Efficace, Patrick Therasse, Martine J Piccart, et al.
The Lancet. Oncology|May 3, 2005
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trialAndrew Bottomley, Patrick Therasse, Martine Piccart, et al.
Blood Advances|January 26, 2026
Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trialInna Y Gong, John Kuruvilla, Anca Prica, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White PaperDavid F Schaeffer, Jennifer Chan, Jason Morin, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Blood|May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011John C Byrd, Kanti Rai, Bercedis L Peterson, et al.
Oncotarget|April 9, 2016
A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trialMelanie Spears, Nicola Lyttle, Alister D'Costa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011Vicki A Morrison, Kanti R Rai, Bercedis L Peterson, et al.
Cancer|September 24, 2004
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)Michael Crump, Tara Baetz, Stephen Couban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16Michael Crump, Stefan Gluck, Dongsheng Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplantA Keith Stewart, Christine I Chen, Kang Howson-Jan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter studyFabio Efficace, Patrick Therasse, Martine J Piccart, et al.
The Lancet. Oncology|May 3, 2005
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trialAndrew Bottomley, Patrick Therasse, Martine Piccart, et al.
Blood Advances|January 26, 2026
Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trialInna Y Gong, John Kuruvilla, Anca Prica, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White PaperDavid F Schaeffer, Jennifer Chan, Jason Morin, et al.
Pageof 10